New 4ml vial gives veterinary surgeons control by providing an assured injectable treatment course, relieving clients of the burden of daily dosing.
Zoetis has introduced a Convenia 4ml vial, continuing the company’s commitment to the “Respect Antibiotics” campaign, which encourages careful and informed selection of appropriate antibiotic therapies for the treatment of dogs and cats.
Convenia gives veterinary surgeons control by providing an assured injectable treatment course, relieving clients of the burden of daily dosing. This avoids missed or mistimed doses, lost tablets, or courses stopped too soon, thereby eliminating a major reason for treatment failure, non-compliance.
Poor compliance is also a significant factor in the development of antimicrobial resistance.
Convenia is licensed for skin, soft tissue and urinary tract infections in dogs and cats, as well as severe gingivitis/periodontitis in dogs (as an adjunct to mechanical or surgical periodontal therapy).
A 4ml vial can treat up to 40Kg of bodyweight, and makes an ideal choice in practice for treating cats and smaller dogs.
Product manager Andrew Page said: “We are committed to encouraging responsible antibiotic usage, and reducing the incidence of antibiotic resistance. Non-compliance plays a key role in the development of antibiotic resistance and we hope that by making Convenia more accessible through the introduction of a 4ml vial we can help alleviate compliance issues.”
- For further details about Convenia please contact your Zoetis account manager.